Better Therapeutics Announces Issuance of U.S. Patent Covering Key Features of Their Prescription Digital Therapeutics Platform
June 08 2022 - 7:30AM
Business Wire
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital
therapeutics (PDT) company developing nutritional cognitive
behavioral therapy (nCBT) to address the root causes of
cardiometabolic diseases, today announced that the U.S. Patent and
Trade Office (USPTO) has granted their first patent, granting
twenty years of exclusivity for a number of key features core to
the company’s digital therapeutics platform, designed to help treat
cardiometabolic diseases through the delivery of digital behavioral
therapy as a PDT.
“Our team has been on the cutting edge of using software to help
individuals change the behaviors that are the underlying causes of
cardiometabolic conditions like type 2 diabetes and fatty liver
disease,” said Kevin Appelbaum, CEO of Better Therapeutics. “This
work has resulted in a number of new and distinct inventions, and
we are proud that this ingenuity has now been officially recognized
by the USPTO.”
The new patent, U.S. Patent No. 11,355,228 granted on June 7th,
2022, is titled “SYSTEM, METHODS, AND APPARATUSES FOR MANAGING DATA
FOR ARTIFICIAL INTELLIGENCE SOFTWARE AND MOBILE APPLICATIONS IN
DIGITAL HEALTH THERAPEUTICS,” and covers methods and apparatus for
generating and monitoring a therapy regimen employing Better
Therapeutics’ innovative machine learning techniques. Taken
together with the 510 days of patent term adjustment provided by
the U.S. Patent and Trademark Office, Better Therapeutics’
exclusivity will extend until at least September of 2039, absent
any further patent extensions.
The mechanisms covered in the patent are core to Better
Therapeutics’ digital platform and relate to the way in which it
uses machine learning and artificial intelligence to personalize
treatment for each patient in order to optimize adherence and
outcomes. Better Therapeutics remains on track to file its de novo
submission to FDA for its first product - BT-001, a treatment for
type 2 diabetes – following the completion of its pivotal clinical
trial this month.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy to
address the root causes of cardiometabolic diseases. The company
has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The cognitive behavioral therapy
delivered by Better Therapeutics’ PDT is designed to enable changes
in neural pathways of the brain so lasting changes in behavior
become possible. Addressing the underlying causes of these diseases
has the potential to dramatically improve patient health while
lowering healthcare costs. Better Therapeutics clinically validated
mobile applications are intended to be prescribed by physicians and
reimbursed like traditional medicines.
For more information visit: bettertx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220608005320/en/
Investor Relations: Mark Heinen IR@bettertx.com
Media: Peter Duckler at Real Chemistry
pduckler@realchemistry.com
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Sep 2023 to Sep 2024